Safety of Beta-Blocker Administration in STEMI Patients With Risk Factors for Cardiogenic Shock

Area of Science:

• Cardiology
• Pharmacology

Background:

• Beta-blockers are recommended post-ST-segment elevation myocardial infarction (STEMI) but cautioned in patients at risk of cardiogenic shock.
• Guideline-defined risk factors for cardiogenic shock include advanced age, hypotension, and heart rate abnormalities.

Purpose of the Study:

• To evaluate the association between early beta-blocker administration and the development of cardiogenic shock in STEMI patients.
• To identify predictors of cardiogenic shock in STEMI patients undergoing percutaneous coronary intervention (PCI).

Main Methods:

• Retrospective cohort study of 216 adult STEMI patients undergoing PCI.
• Patients were stratified based on beta-blocker administration within 24 hours of PCI.
• Multivariable logistic regression analysis was employed to assess the association between early beta-blocker use and cardiogenic shock, controlling for risk factors.

Main Results:

• Early beta-blocker administration was not significantly associated with a lower incidence of cardiogenic shock (aOR 0.334, P=0.0599).
• Patients with a peak troponin level over 56 ng/mL had a significantly increased risk of developing cardiogenic shock (aOR 3.434, P=0.0224).
• The incidence of cardiogenic shock was 4.7% in the early beta-blocker group versus 12.2% in the no-early-beta-blocker group (P=0.0909).

Conclusions:

• Early beta-blocker administration in STEMI patients does not appear to increase the risk of cardiogenic shock.
• Peak troponin levels are a significant predictor of cardiogenic shock development in STEMI patients.
• Risk stratification for cardiogenic shock should consider biomarkers like troponin alongside traditional risk factors.